INTRODUCTION Acute otitis media is an inflammation of the middle ear that usually results from infection. When fluid accompanies the inflammation, the condition is known as otitis media with effusion. Tympanostomy tubes are commonly inserted to treat recurrent otitis media with effusion. In the U.S., approximately two million tympan-ostomy tubes are inserted annually. The estimated [...]
The potential for drug interactions with ximelagatran has been described in various in vitro and in vivo studies. In general, ximelagatran demonstrated a low potential for drug interactions based on several factors: The mechanism of action of ximela-gatran was not affected by vitamin K-dependent clotting factors. The plasma protein binding of mela-gatran was relatively low. [...]
The Oral Direct Thrombin inhibitor, ximelagatran, for Fenous Thromboembolism (THRIVE) study, a multi-center, double-blind trial, included 1,233 patients with documented DVT and PE and appropriate anticoagulation therapy for six months’ duration. This study evaluated the efficacy and safety of ximela-gatran in preventing secondary events associated with VTE. Inclusion criteria were based on the receipt of [...]
Ximelagatran is an oral pro-drug of melagatran, a low-molecular-weight direct thrombin inhibitor. After oral administration, ximelagatran is rapidly absorbed and is extensively metabolized to its active form of melagatran via hydrolysis and reduction.
INTRODUCTION Since its discovery in the early 1940s, warfarin (Coumadin drug, Bristol-Myers Squibb) has been the leading oral anticoagulant agent for various thrombo-embolic events. A vitamin K antagonist, warfarin is the only clinically available oral anticoagulant. Although it is effective, warfarin has certain limitations (Table 1) that make its use complex.
© 2008 HIV/AIDS News & Information